Determining the Delamanid Pharmacokinetics/Pharmacodynamics Susceptibility Breakpoint Using Monte Carlo Experiments-Reference-Cited by-同舟云学术

Determining the Delamanid Pharmacokinetics/Pharmacodynamics Susceptibility Breakpoint Using Monte Carlo Experiments

Published:2023-04-18 Issue:4 Volume:67 Page:
ISSN:0066-4804
Container-title:Antimicrobial Agents and Chemotherapy
language:en
Short-container-title:Antimicrob Agents Chemother

Author:

Liu Yongge¹^ORCID,Moodley Mischka²^ORCID,Pasipanodya Jotam G.³,Gumbo Tawanda³^ORCID

Affiliation:

1. Otsuka Pharmaceutical Development & Commercialization, Inc., Rockville, Maryland, USA

2. Otsuka Novel Products GmbH, Munich, Germany

3. Quantitative Preclinical & Clinical Sciences Department, Praedicare Inc., Dallas, Texas, USA

Abstract

Antimicrobial susceptibility testing, based on clinical breakpoints that incorporate pharmacokinetics/pharmacodynamics (PK/PD) and clinical outcomes, is becoming a new standard in guiding individual patient therapy as well as for drug resistance surveillance. However, for most antituberculosis drugs, breakpoints are instead defined by the epidemiological cutoff values of the MIC of phenotypically wild-type strains irrespective of PK/PD or dose.

Funder

OAPI | Otsuka Novel Products GmbH

Publisher

American Society for Microbiology

Subject

Infectious Diseases,Pharmacology (medical),Pharmacology

Link

https://journals.asm.org/doi/pdf/10.1128/aac.01401-22

Reference67 articles.

1. World Health Organization. 2018. Technical manual for drug susceptibility testing of medicines used in the treatment of tuberculosis. WHO/CDS/TB/2018.24. WHO, Geneva, Switzerland. https://apps.who.int/iris/bitstream/handle/10665/275469/9789241514842-eng.pdf?sequence=1&isAllowed=y.

2. Serum Drug Concentrations Predictive of Pulmonary Tuberculosis Outcomes

3. Drug Concentration Thresholds Predictive of Therapy Failure and Death in Children With Tuberculosis: Bread Crumb Trails in Random Forests

4. Artificial Intelligence and Amikacin Exposures Predictive of Outcomes in Multidrug-Resistant Tuberculosis Patients

5. Artificial intelligence–derived 3-Way Concentration-dependent Antagonism of Gatifloxacin, Pyrazinamide, and Rifampicin During Treatment of Pulmonary Tuberculosis

Cited by 1 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Pharmacology of emerging drugs for the treatment of multi-drug resistant tuberculosis;Journal of Clinical Tuberculosis and Other Mycobacterial Diseases;2024-12